Crescent Biopharma (CBIO) Equity Average (2014 - 2026)
Crescent Biopharma (CBIO) reported Equity Average of $193.4 million for Q1 2026, up 947.63% year-over-year from $18.5 million in Q1 2025, and up 21.02% on a QoQ basis from $159.8 million in Q4 2025.
Crescent Biopharma (CBIO) has 13 years of Equity Average data on file, last reported at $193.4 million in Q1 2026.
- Quarterly Equity Average rose 947.63% year-over-year to $193.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.4 million (up 947.63% YoY) and the FY2025 annual result came in at $93.8 million, up 717.66% from the prior year.
- Equity Average climbed to $193.4 million in Q1 2026 per CBIO's latest filing, from $159.8 million in the prior quarter.
- Across five years, Equity Average topped out at $193.4 million in Q1 2026 and bottomed at -$22.8 million in Q1 2025.
- The 5-year median for Equity Average is $51.9 million (2022), against an average of $59.4 million.
- Peak annual rise in Equity Average reached 2004.85% in 2025, while the deepest fall reached 167.79% in 2025.
- Tracing CBIO's Equity Average over 5 years: stood at $45.5 million in 2022, then retreated by 6.68% to $42.5 million in 2023, then slumped by 119.75% to -$8.4 million in 2024, then surged by 2004.85% to $159.8 million in 2025, then grew by 21.02% to $193.4 million in 2026.
- Per Business Quant, the three latest CBIO Equity Average figures stand at $193.4 million (Q1 2026), $159.8 million (Q4 2025), and $127.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 193.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193.43 Mn |
| Dec 31, 2025 | 159.83 Mn |
| Sep 30, 2025 | 127.95 Mn |
| Jun 30, 2025 | 54.55 Mn |
| Mar 31, 2025 | -22.82 Mn |
| Dec 31, 2024 | -8.39 Mn |
| Sep 30, 2024 | 9.38 Mn |
| Jun 30, 2024 | 24.49 Mn |
| Mar 31, 2024 | 33.66 Mn |
| Dec 31, 2023 | 42.48 Mn |
| Sep 30, 2023 | 50.67 Mn |
| Jun 30, 2023 | 58.49 Mn |
| Mar 31, 2023 | 52.56 Mn |
| Dec 31, 2022 | 45.52 Mn |
| Sep 30, 2022 | 51.92 Mn |
| Jun 30, 2022 | 61.88 Mn |
| Mar 31, 2022 | 74.82 Mn |
| Dec 31, 2021 | 89.08 Mn |
| Sep 30, 2021 | 104.43 Mn |
| Jun 30, 2021 | 118.70 Mn |
| Mar 31, 2021 | 126.67 Mn |
| Dec 31, 2020 | 133.24 Mn |
| Sep 30, 2020 | 142.01 Mn |
| Jun 30, 2020 | 147.12 Mn |
| Mar 31, 2020 | 151.35 Mn |
| Dec 31, 2019 | 160.64 Mn |
| Sep 30, 2019 | 172.82 Mn |
| Jun 30, 2019 | 185.68 Mn |
| Mar 31, 2019 | 199.13 Mn |
| Dec 31, 2018 | 211.78 Mn |
| Sep 30, 2018 | 223.05 Mn |
| Jun 30, 2018 | 233.02 Mn |
| Mar 31, 2018 | 178.87 Mn |
| Dec 31, 2017 | 114.13 Mn |
| Sep 30, 2017 | 112.00 Mn |
| Jun 30, 2017 | 73.66 Mn |
| Mar 31, 2017 | 33.59 Mn |
| Dec 31, 2016 | 38.53 Mn |
| Sep 30, 2016 | 45.31 Mn |
| Jun 30, 2016 | 41.82 Mn |
| Mar 31, 2016 | 37.62 Mn |
| Dec 31, 2015 | 44.59 Mn |
| Sep 30, 2015 | 51.96 Mn |
| Jun 30, 2015 | 49.79 Mn |
| Mar 31, 2015 | 47.58 Mn |
| Dec 31, 2014 | 54.26 Mn |
| Sep 30, 2014 | 60.80 Mn |
| Jun 30, 2014 | 59.62 Mn |
| Mar 31, 2014 | 29.13 Mn |